Safety and Effectiveness of Bexagliflozin in Patients With Type 2 Diabetes Mellitus and Stage 3a/3b CKD.

ABSTRACT:

Rationale & objective

Hyperglycemia exacerbates the progression of chronic kidney disease (CKD), but most glucose-lowering therapies do not address morbidities associated with CKD. Sodium/glucose cotransporter 2 (SGLT2) inhibitors offer potential benefits to patients with diabetes and CKD, but their effectiveness may be diminished with decreased kidney function. We aimed to evaluate the safety and effectiveness of bexagliflozin, a novel SGLT2 inhibitor, in patients with type 2 diabetes and CKD.

Study design

Phase 3, double-blind, placebo-controlled, multicenter, multinational, randomized trial.

Setting & participants

54 sites across 4 countries. Patients with CKD stage 3a or 3b, type 2 diabetes mellitus, and hemoglobin A_1c level of 7.0% to 10.5% and estimat

SUBMITTER: Allegretti AS 

PROVIDER: S-EPMC10077840 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature